Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 26, 2009
Wed, February 25, 2009 RTI Biologics Launches Two Biologic Implants at Orthopaedic Surgeon Annual Meeting
ALACHUA, Fla.--([ BUSINESS WIRE ])--RTI Biologics, Inc. (RTI) (Nasdaq:RTIX), the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching two new biologic implants for use in sports medicine surgeries at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in Las Vegas this week. Matrix HD™, the first RTI dermis graft for sports medicine, and fresh-stored osteochondral (OC) talus allograft, an expansion of RTI's fresh OC line, are both now available through RTI's direct representatives and distributors.
Matrix HD
Matrix HD heralds RTI's entry into the augmentation graft market and is the first crossover implant opportunity from the 2008 merger of RTI and Tutogen Medical, Inc. Matrix HD is acellular human dermis sterilized through Tutoplast®, using the same processing technology that has been clinically successful for membrane implants used in hernia, dental and other surgical specialties for more than 30 years.
Matrix HD is comprised of collagenous connective tissue with three-dimensional intertwined fibers that retain the multidirectional and mechanical properties of native dermis, while providing the basic structure to support the patient's own tissue regeneration. The implant is offered in multiple sizes to accommodate particular soft tissue defects and surgeon need.
For the surgeon, Matrix HD provides a sterile allograft dermis implant to supplement, support, protect and reinforce tissue in augmentation procedures of the rotator cuff, anterior shoulder capsule, patellar tendon, quadriceps tendon and Achilles tendon.
Fresh-stored OC Talus Allograft
RTI is expanding its fresh-stored OC line with the introduction of the fresh-stored OC talus allograft. The fresh-stored OC talus enables surgeons to resurface cartilage defects in the ankle with mature hyaline cartilage and healthy subchondral bone in a single procedure.
Hyaline cartilage is the specific type of cartilage that has poor healing and repair properties once damaged. When damage to the articular surface occurs, a fresh-stored allograft with viable cartilage cells is preferred for optimal healing as compared to frozen allograft cartilage.
RTI Fresh-stored OC Talus grafts are cleansed, processed and preserved in an effort to provide a safe, high-quality allograft with a high level of chondrocyte viability, or live cartilage cells.
RTI uses expedited release criteria to maintain fresh-stored graft utility. Like all RTI tissue, extensive donor screening in accordance with Food and Drug Administration (FDA) and American Association of Tissue Banks (AATB) requirements is conducted. In addition to serological testing, state of the art microbiological testing – which includes testing for bacterial spores and fungi – is used throughout the process to screen for potential contamination. Additionally, all fresh-stored OC allografts are placed in a proprietary antibiotic soak developed by RTI to reduce potential contaminants. Grafts are then packaged in a nutrient media and stored refrigerated for up to 45 days.
AP and Lateral radiographs are used to size-match grafts to awaiting patients and are currently being accepted by RTI for the fresh-stored allograft line.
Information and demonstrations for both Matrix HD and the fresh-stored OC talus implants will be available at the AAOS meeting, booth #4065. For further information, contact an RTI representative at (800) 624-7238.
About RTI Biologics, Inc.
RTI Biologics, Inc. prepares human donated tissue and bovine tissue for transplantation with a commitment to advancing science, safety and innovation. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.
RTI's innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® process – sterilize tissue, are clinically successful and are scientifically proven to eliminate donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of more than a million implants distributed with zero incidence of graft-related infection. In addition, RTI demineralized bone is processed through the Cancelle SP™ DBM Sterilization Process, which includes a validated viral inactivation step.
RTI's worldwide corporate headquarters and processing facilities are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks. Visit RTI's Web site at [ www.rtix.com ] for more information.
Forward Looking Statement
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about the expected benefits of the business combination involving RTI and Tutogen, including potential synergies and cost savings, future financial and operating results, and the combined company's plans and objectives. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results, regulatory approvals or changes to agreements with distributors also are forward-looking statements. Forward-looking statements are subject to risks and uncertainties, including the ability of RTI to integrate its business successfully and to realize the expected synergies and cost savings from the merger and the risks described in public filings on file with the United States Securities and Exchange Commission (SEC). Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's Web site at [ www.rtix.com ] or the SEC's Web site at [ www.sec.gov ].
